TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02394665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Concurrently during radiation therapy. Adjuvant therapy administered daily on days 1 - 5 for 12 cycles. One cycle = 28 days:~* Concurrent during Radiation Therapy: 75 mg/m\^2 orally for 6 weeks;~* Post-radiation, adjuvant therapy: 150 mg/m\^2 - 200 mg/m\^2 orally daily on days 1 - 5 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Concurrently during radiation therapy. Adjuvant therapy administered daily on days 1 - 5 for 12 cycles. One cycle = 28 days:~* Concurrent during Radiation Therapy: 75 mg/m\^2 orally for 6 weeks;~* Post-radiation, adjuvant therapy: 150 mg/m\^2 - 200 mg/m\^2 orally daily on days 1 - 5 of each cycle.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Assessment of Cancer Therapy-Brain (FACT-Br)
Description: FACT-Br Quality of Life (QOL) questionnaire to be completed by study patients as protocol specific timepoints

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Assessment of Cancer Therapy-Brain (FACT-Br)
Description: FACT-Br Quality of Life (QOL) questionnaire to be completed by study patients as protocol specific timepoints

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery Boost
Description: Patients will undergo SRS boost in a single fraction dose prior to IMRT treatment:~HTV Maximum dimension vs. Prescribed Dose to HTV: ≤ 20 mm = 21 Gy; 21 mm - 30 mm = 18 Gy; 31 mm - 40 mm = 15 Gy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Simultaneous Integrated Boost
Description: Treatment shall consist of 60 Gy in 30 fractions to planning target volume (PTV) 60 and 75 Gy in 30 fractions to PTV 75.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D MRSI
Description: Three Dimensional Magnetic Resonance Spectroscopy Imaging (MRSI) during pre-treatment, week 3 during radiation therapy, end of radiation therapy; will include standard gadolinium enhanced MRI prior to cycle 1, 5, 9, and post cycle 12 of adjuvant temozolomide therapy, per protocol.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D MRSI
Description: Three Dimensional Magnetic Resonance Spectroscopy Imaging (MRSI) during pre-treatment, week 3 during radiation therapy, end of radiation therapy; will include standard gadolinium enhanced MRI prior to cycle 1, 5, 9, and post cycle 12 of adjuvant temozolomide therapy, per protocol.
Study: NCT01056263

Intervention type: DRUG
Intervention: axitinib: observational study
Description: Non-interventional observational study
Study: NCT03981497

Intervention type: PROCEDURE
Intervention: Microwave ablation (MWA)
Description: Thermal ablation

Intervention type: PROCEDURE
Intervention: Microwave ablation (MWA)
Description: Thermal ablation
Study: NCT03860090

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker implant
Description: Implantation of endovenous cardiac stimulation device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker implant
Description: Implantation of endovenous cardiac stimulation device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Defibrillator implant
Description: Implantation of endovenous cardiac defibrillation device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Defibrillator implant
Description: Implantation of endovenous cardiac defibrillation device.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AXILLARY VEIN ACCESS
Description: Fluoroscopy-guided axillary puncture to get vein access

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CEPHALIC VEIN ACCESS
Description: Optimized cephalic vein cutdown to get vein access
Study: NCT02014883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLUT1 DS
Study: NCT03900429

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MGL-3196
Description: Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MGL-3196
Description: Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Tablets

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Liver Biopsy
Description: A procedure in which a needle is inserted into the liver to collect a tissue sample

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Liver Biopsy
Description: A procedure in which a needle is inserted into the liver to collect a tissue sample

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Liver Biopsy
Description: A procedure in which a needle is inserted into the liver to collect a tissue sample
Study: NCT04403906

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PCL COV05 - COVID 19 Ag Rapid FIA test (Rapid Antigen Test)
Description: The PCL COV05 - COVID 19 Ag Rapid FIA test has FSC and CE approvals for the qualitative detection of SARS-CoV-2 Antigens from human oropharyngeal swabs and deep sputum samples. The manufacturer is PCL Corporation Ltd 17F, 128 B-dong, Courthouse-ro, Songpa-gu, Seoul, South Korea.
Study: NCT03371823

Intervention type: OTHER
Group type: OTHER
Intervention: Normotensive
Description: FMD is a measure of endothelial function by assessing the degree to which vessel dilates in response to increased flow. Pulse Wave Analysis and Pulse Wave Velocity assesses arterial stiffness and wave reflection in all women. Laser Doppler flowmetry is used in combination with cutaneous microdialysis as a minimally invasive technique to examine mechanisms of vascular function. ET-B and ET-A receptor antagonists will be perfused via intradermal microdialysis fibers while measuring cutaneous blood flow. ET-1 production and ET-B receptor expression in endothelial cells collected from an antecubital vein will also be assessed. Immunohistochemistry will be performed on skin punch biopsy samples to assess for protein expression of ET-A and ET-B receptors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertensives
Description: ANG II increases the synthesis of ET-1 and alters ET-A/B receptor expression, thus affecting ET-1 bioavailability. Losartan is an ANG II receptor antagonist which attenuates ET-1 production. Losartan 50 mg daily is administered for 14 days to hypertensive women. FMD is used to measure endothelial function. Pulse Wave Analysis and Pulse Wave Velocity assesses arterial stiffness and wave reflection. Laser Doppler flowmetry with cutaneous microdialysis is used to examine vascular function when ET-A and ET-B receptor antagonists is perfused via intradermal microdialysis fibers. ET-1 production and ET-B receptor expression in endothelial cells collected from an antecubital vein will be assessed. Skin punch biopsy samples will be used to assess for protein expression of ET-A and ET-B receptors.
Study: NCT02328586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group Acupuncture
Study: NCT03259399

Intervention type: GENETIC
Intervention: detection of genotype
Description: detection of genotype by next generation sequencing

Intervention type: GENETIC
Intervention: detection of genotype
Description: detection of genotype by next generation sequencing
Study: NCT00693433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04615598

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action observation
Description: The idea is to show some videos with the aim of improving patients' tongue strength.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: The idea is to show some videos of vegetation with the aim of having an intervention time but ineffective.
Study: NCT00139581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimecrolimus
Description: Pimecrolimus cream 1 % applied twice daily (b.i.d.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimecrolimus
Description: Pimecrolimus cream 1 % applied once daily (o.d.) and placebo applied once daily (o.d.)
Study: NCT02351713

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Continuous aerobic exercise prescribed according to two exercise intensity methods: threshold based method (i.e., ventilatory threshold) and relative percent method (i.e., heart rate reserve).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Continuous aerobic exercise prescribed according to two exercise intensity methods: threshold based method (i.e., ventilatory threshold) and relative percent method (i.e., heart rate reserve).
Study: NCT01965509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEX168 or placebo
Description: injection has to administered subcutaneously weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEX168 or placebo
Description: injection has to administered subcutaneously weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PEX168 or placebo
Description: injection has to administered subcutaneously weekly
Study: NCT00702598

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-based Cognitive Behaviour Therapy (CBT)
Description: Telephone-based CBT: Eight sessions of telephone-based CBT (Tel-CBT) will be delivered over 8-10 weeks, based on a published manual (Simon et al, 2004). Tel-CBT has been modified to be briefer than traditional CBT (30-40 minutes instead of 60 minutes per session) and will be offered at convenient times (including evening sessions). The initial Tel-CBT session will occur within 2 weeks of randomization, with subsequent sessions occurring every 1-2 weeks depending on scheduling and patient preference. The initial session focuses on motivation enhancement exercises, subsequent sessions emphasize identifying, challenging and distancing from negative thoughts, and the final session focuses on a personal care plan and self-management skills.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Telephone reminder calls
Description: Telephone reminder calls: Weekly telephone calls for 8 weeks to inquire on progress and remind patients to take their medications properly
Study: NCT02536495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given PO
Study: NCT03993561

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment summary and survivorship care plan
Description: Individually tailored counselling session will be implemented within 1 month of treatment completion.
Study: NCT02972242

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Field of View
Description: Non-Contrast CT Scan for coronary calcium assessment prior to CT coronary angiography

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Field of View
Description: Non-Contrast CT Scan for coronary calcium assessment prior to CT coronary angiography
Study: NCT02003690

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy
Description: Dialectical Behavior Therapy
Study: NCT01894971

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Effect of Ligasure® to Destroy Cornual Portion of Fallopian Tube
Study: NCT02003690

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Psychotherapy
Description: Standard of Care Psychotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Description: Standard of Care Pharmacotherapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacotherapy
Description: Standard of Care Pharmacotherapy
Study: NCT00174798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSR240600C
Description: once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine
Description: once daily
Study: NCT03647202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milademetan Treatment A
Description: Treatment A: Single oral dose of milademetan 160 mg capsules under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milademetan Treatment A
Description: Treatment A: Single oral dose of milademetan 160 mg capsules under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milademetan Treatment A
Description: Treatment A: Single oral dose of milademetan 160 mg capsules under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milademetan Treatment A
Description: Treatment A: Single oral dose of milademetan 160 mg capsules under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milademetan Treatment A
Description: Treatment A: Single oral dose of milademetan 160 mg capsules under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milademetan Treatment A
Description: Treatment A: Single oral dose of milademetan 160 mg capsules under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milademetan Treatment B
Description: Treatment B: Single oral dose of milademetan 160 mg capsules with a high-calorie, high-fat meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milademetan Treatment B
Description: Treatment B: Single oral dose of milademetan 160 mg capsules with a high-calorie, high-fat meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milademetan Treatment B
Description: Treatment B: Single oral dose of milademetan 160 mg capsules with a high-calorie, high-fat meal
Study: NCT04865991

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TCI Propofol
Description: Peripheral venous catheters were placed in all subjects. Subjects in the TCI propofol group had one specific intravenous catheter for propofol infusion apart from medication or intravenous fluid line. Subjects in the TCI Propofol group received TCI propofol (Schneider) with targeted Ce 4 -5 mcg/ml for anesthesia induction and maintenance. Subjects in the TCI propofol group received TCI propofol for anesthesia maintenance, Ce value was titrated until a targeted BIS score of 40-60 achieved.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: subjects in the sevoflurane group were cannulated only with one venous catheter. Midazolam 0.05 mg/kg BW and fentanyl 1 mcg/kg BW were given as premedication. Subjects in the sevoflurane group received intravenous propofol 1 - 2 mg/kg BW.
Study: NCT02227368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Antiplatelet therapy approved for ACS. Antagonist of P2Y12 and inhibitor of adenosine diphosphate (ADP)-induced platelet aggregation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator
Description: Aspirin monotherapy anti-platelet treatment for PAD patients following EVR procedures
Study: NCT01981070

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness Intervention for Parents
Description: See Study Arms

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Support and Information for Parents
Description: See Study Arms
Study: NCT02578459

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrathecal Drug Delivery System
Description: The Prometra Pump is a battery-operated, implantable, programmable infusion pump that dispenses pain medication into the intrathecal space through an implanted infusion catheter.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Medical Management
Description: Treatment with conventional medical management will include using standard systemic pain medications such as narcotics, nonsteroidal anti-inflammatory drugs (NSAIDs), and neuropathic medications (examples: gabapentin, Lyrica, Cymbalta) that are typically used to treat pancreatic cancer pain.
Study: NCT03189069

Intervention type: DRUG
Intervention: Apixaban
Description: Treatment for NVAF patients

Intervention type: DRUG
Intervention: Dabigatran
Description: Treatment for NVAF patients

Intervention type: DRUG
Intervention: Rivaroxaban
Description: Treatment for NVAF patients

Intervention type: DRUG
Intervention: Warfarin
Description: Treatment for NVAF patients
Study: NCT01197014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine plus Losartan
Description: Amlodipine/Losartan high dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine, Losartan
Description: Amlodipine, Losartan
Study: NCT00534105

Intervention type: OTHER
Intervention: Total Cholesterol

Intervention type: OTHER
Intervention: Total Cholesterol

Intervention type: OTHER
Intervention: Triglyceride

Intervention type: OTHER
Intervention: Triglyceride

Intervention type: OTHER
Intervention: HDL

Intervention type: OTHER
Intervention: HDL

Intervention type: OTHER
Intervention: LDL

Intervention type: OTHER
Intervention: LDL
Study: NCT03647202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milademetan Treatment B
Description: Treatment B: Single oral dose of milademetan 160 mg capsules with a high-calorie, high-fat meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milademetan Treatment B
Description: Treatment B: Single oral dose of milademetan 160 mg capsules with a high-calorie, high-fat meal
Study: NCT03827551

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delivery of oral hygiene advices
Description: Patients will benefit from hygiene advice and maintenance of good oral health. No treatment will be administered as part of this study. Patients will continue their usual treatment according to the contraindications. Patients will benefit from salivary sampling and a collection of oral bacteria contained in the dental plaque using paper tips. These reviews will be conducted during the Inclusion Visit and the 6 month Follow-Up Visit.
Study: NCT02532452

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Viral Specific VST Infusion
Description: VSTs will be infused into immunocompromised patients with evidence of viral infection or reactivation defined as any of the following:~* Blood adenovirus PCR ≥ 1,000~* Blood CMV PCR ≥ 500~* Blood EBV PCR ≥ 9,000~* Plasma BKV PCR \>1,000~* Plasma JC Virus PCR \> 1,000~* Evidence of invasive adenovirus infection or disease, defined as the presence of adenoviral positivity by PCR or culture in one or more sites~* Evidence of invasive CMV infection, eg pneumonitis, retinitis, colitis~* Evidence of invasive EBV disease/infection, EBV-associated lymphoproliferation (EBV-LPD) defined as proven EBV-LPD by biopsy or probable EBV-LPD defined as an elevated EBV DNA level in the blood associated with clinical symptoms (adenopathy or fever or masses on imaging) but without biopsy confirmation, or EBV-associated malignancies~* Evidence of symptomatic BK virus infection, which may include symptomatic hemorrhagic cystitis, or BK nephropathy~* Evidence of PML or other CNS infection due to JC virus
Study: NCT01196936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen Citrate
Description: 5 mg PO Daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet daily

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Digital mammography
Description: Correlative studies

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Digital mammography
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative Studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: immunohistochemistry staining method
Description: Correlative Studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative Studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: pharmacological study
Description: Correlative Studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative Studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative Studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Description: correlative studies

Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: protein expression analysis
Description: correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies
Description: correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: pharmacogenomic studies
Description: correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fine needle aspiration

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Fine needle aspiration
Study: NCT03647202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milademetan Treatment B
Description: Treatment B: Single oral dose of milademetan 160 mg capsules with a high-calorie, high-fat meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milademetan Treatment C
Description: Treatment C: Single oral dose of milademetan 160 mg capsules with a standard meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milademetan Treatment C
Description: Treatment C: Single oral dose of milademetan 160 mg capsules with a standard meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milademetan Treatment C
Description: Treatment C: Single oral dose of milademetan 160 mg capsules with a standard meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milademetan Treatment C
Description: Treatment C: Single oral dose of milademetan 160 mg capsules with a standard meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milademetan Treatment C
Description: Treatment C: Single oral dose of milademetan 160 mg capsules with a standard meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milademetan Treatment C
Description: Treatment C: Single oral dose of milademetan 160 mg capsules with a standard meal.